FindTrial
Sign In

sigvotatug vedotin

DRUG6 trials

Sponsors

Pfizer Inc., Seagen, a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Advanced/Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Cutaneous Squamous Cell CancerEsophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaExocrine Pancreatic Adenocarcinoma

Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingNCT04389632
Seagen, a wholly owned subsidiary of PfizerCarcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer, Esophageal Adenocarcinoma +9
Start: 2020-06-08End: 2029-03-22Target: 1006Updated: 2026-03-16
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
CompletedNCT06549816
Seagen, a wholly owned subsidiary of PfizerCarcinoma, Non-Small Cell Lung, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma +3
Start: 2024-08-21End: 2025-11-18Updated: 2025-12-15
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RecruitingNCT07227298
PfizerAdvanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Start: 2026-01-30End: 2033-08-23Target: 162Updated: 2026-03-02

Phase 3

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Active, not recruitingNCT06012435
Seagen, a wholly owned subsidiary of PfizerCarcinoma, Non-Small-Cell Lung
Start: 2024-02-21End: 2028-03-11Updated: 2026-03-18
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingNCT06758401
PfizerCarcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Non-Small Cell Lung Cancer
Start: 2025-07-23End: 2029-03-01Target: 714Updated: 2026-03-12
C5751003 - AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER)
RecruitingCTIS2024-517968-36-00
Pfizer Inc.non-small cell lung cancer
Start: 2025-07-08Target: 269Updated: 2025-11-05

Related Papers

Data from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
2025-12-17
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.
2025-12-13
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).
Journal of Clinical Oncology2025-05-281 citations
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design
2025-01-01
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design
2025-01-01
Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).
Journal of Clinical Oncology2024-06-015 citations
SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Molecular Cancer Therapeutics2023-08-2417 citations
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
Journal of Clinical Oncology2023-06-0110 citations
Abstract 1522: SGN-B6A induces immunogenic cell death as an additional mechanism of action
Cancer Research2023-04-042 citations
731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)
Regular and Young Investigator Award Abstracts2022-11-013 citations
1186 SGN-B6A induces immunogenic cell death as a secondary mechanism of action
Regular and Young Investigator Award Abstracts2022-11-01
Abstract 914: Activity of SGN-B6A in patient-derived xenograft models of non-small cell lung cancer
Cancer Research2021-07-01
A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
Journal of Clinical Oncology2021-05-207 citations